IDH2 and cancer: The finding that IDH1 and IDH2 mutations occur in various other cancer types has spurred further interest in cancer metabolism, epigenetic regulation, and therapeutic targeting, also promoting the idea that these mutations drive tumorigenesis in general [1,2,3,4,5,21], despite how IDH1 and IDH2 mutations promote gliomagenesis remains unclear [13,22].